Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 761 entries
Sorted by: Best Match Show Resources per page
Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation.

International journal of organ transplantation medicine

Issa D, Eghtesad B, Zein NN, Yerian L, Cruise M, Alkhouri N, Adams R, Hanouneh IA.
PMID: 26889372
Int J Organ Transplant Med. 2016;7(1):38-45. Epub 2016 Feb 01.

Fibrosing cholestatic hepatitis (FCH) is an aggressive form of hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT), which frequently results in graft failure and death. Treatment of FCH remains challenging, and the optimal antiviral therapy is yet...

Cite
Issa D, Eghtesad B, Zein NN, et al. Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation. Int J Organ Transplant Med. 2016;7(1):38-45
Issa, D., Eghtesad, B., Zein, N. N., Yerian, L., Cruise, M., Alkhouri, N., Adams, R., & Hanouneh, I. A. (2016). Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation. International journal of organ transplantation medicine, 7(1), 38-45.
Issa, D, et al. "Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation." International journal of organ transplantation medicine vol. 7,1 (2016): 38-45.
Issa D, Eghtesad B, Zein NN, Yerian L, Cruise M, Alkhouri N, Adams R, Hanouneh IA. Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation. Int J Organ Transplant Med. 2016;7(1):38-45. Epub 2016 Feb 01. PMID: 26889372; PMCID: PMC4756263.
Copy Download .nbib Format: NLM
Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals.

Hepatology research : the official journal of the Japan Society of Hepatology

Kurata H, Uchida Y, Kouyama JI, Naiki K, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S.
PMID: 28872737
Hepatol Res. 2018 Feb;48(3):E372-E378. doi: 10.1111/hepr.12977. Epub 2017 Sep 25.

A 40-year-old male patient with virologic relapse after daclatasvir plus asunaprevir therapy for a serogroup 1 hepatitis C virus (HCV) infection visited our hospital for retreatment. Virologic examinations revealed that a genotype 2b HCV strain carrying both NS3-S122N /...

Cite
Kurata H, Uchida Y, Kouyama JI, et al. Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals. Hepatol Res. 2017;48(3):E372-E378doi: 10.1111/hepr.12977.
Kurata, H., Uchida, Y., Kouyama, J. I., Naiki, K., Nakazawa, M., Ando, S., Nakao, M., Motoya, D., Sugawara, K., Inao, M., Imai, Y., Nakayama, N., Tomiya, T., & Mochida, S. (2018). Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals. Hepatology research : the official journal of the Japan Society of Hepatology, 48(3), E372-E378. https://doi.org/10.1111/hepr.12977
Kurata, Hayato, et al. "Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals." Hepatology research : the official journal of the Japan Society of Hepatology vol. 48,3 (2018): E372-E378. doi: https://doi.org/10.1111/hepr.12977
Kurata H, Uchida Y, Kouyama JI, Naiki K, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S. Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals. Hepatol Res. 2018 Feb;48(3):E372-E378. doi: 10.1111/hepr.12977. Epub 2017 Sep 25. PMID: 28872737.
Copy Download .nbib Format: NLM
Post-liver transplant hepatitis C therapy.

Current treatment options in gastroenterology

Rahimi RS, O'Leary JG.
PMID: 25809738
Curr Treat Options Gastroenterol. 2015 Jun;13(2):249-58. doi: 10.1007/s11938-015-0051-1.

OPINION STATEMENT: Pharmacologic therapies to treat chronic hepatitis C virus (HCV) have rapidly evolved over the past few years and resulted in short courses of all oral multidrug cocktails of direct-acting antivirals (DAAs) that achieve sustained virologic response (SVR)...

Cite
Rahimi RS, O'Leary JG. Post-liver transplant hepatitis C therapy. Curr Treat Options Gastroenterol. 2015;13(2):249-58doi: 10.1007/s11938-015-0051-1.
Rahimi, R. S., & O'Leary, J. G. (2015). Post-liver transplant hepatitis C therapy. Current treatment options in gastroenterology, 13(2), 249-58. https://doi.org/10.1007/s11938-015-0051-1
Rahimi, Robert S, and O'Leary, Jacqueline G. "Post-liver transplant hepatitis C therapy." Current treatment options in gastroenterology vol. 13,2 (2015): 249-58. doi: https://doi.org/10.1007/s11938-015-0051-1
Rahimi RS, O'Leary JG. Post-liver transplant hepatitis C therapy. Curr Treat Options Gastroenterol. 2015 Jun;13(2):249-58. doi: 10.1007/s11938-015-0051-1. PMID: 25809738.
Copy Download .nbib Format: NLM
Stability-Indicating Method and LC-MS-MS Characterization of Forced Degradation Products of Sofosbuvir.

Journal of chromatographic science

Nebsen M, Elzanfaly ES.
PMID: 27436268
J Chromatogr Sci. 2016 Oct 17;54(9):1631-1640. doi: 10.1093/chromsci/bmw119.

Sofosbuvir is a novel direct acting antiviral agent against hepatitis C virus. In the present work, a rapid, specific and reproducible isocratic reversed phase high performance liquid chromatography (RP-HPLC) method has been developed and validated for the determination of...

Cite
Nebsen M, Elzanfaly ES. Stability-Indicating Method and LC-MS-MS Characterization of Forced Degradation Products of Sofosbuvir. J Chromatogr Sci. 2016;54(9):1631-1640doi: 10.1093/chromsci/bmw119.
Nebsen, M., & Elzanfaly, E. S. (2016). Stability-Indicating Method and LC-MS-MS Characterization of Forced Degradation Products of Sofosbuvir. Journal of chromatographic science, 54(9), 1631-1640. https://doi.org/10.1093/chromsci/bmw119
Nebsen, M, and Elzanfaly, Eman S. "Stability-Indicating Method and LC-MS-MS Characterization of Forced Degradation Products of Sofosbuvir." Journal of chromatographic science vol. 54,9 (2016): 1631-1640. doi: https://doi.org/10.1093/chromsci/bmw119
Nebsen M, Elzanfaly ES. Stability-Indicating Method and LC-MS-MS Characterization of Forced Degradation Products of Sofosbuvir. J Chromatogr Sci. 2016 Oct 17;54(9):1631-1640. doi: 10.1093/chromsci/bmw119. PMID: 27436268.
Copy Download .nbib Format: NLM
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection.

Therapeutics and clinical risk management

Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G.
PMID: 25061308
Ther Clin Risk Manag. 2014 Jun 26;10:493-504. doi: 10.2147/TCRM.S66731. eCollection 2014.

According to the World Health Organization, approximately 150 million people worldwide are chronic carriers of hepatitis C virus (HCV). HCV infection can evolve into cirrhosis of the liver and its complications, which are ultimately responsible for more than 350,000...

Cite
Gentile I, Buonomo AR, Zappulo E, et al. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag. 2014;10:493-504doi: 10.2147/TCRM.S66731.
Gentile, I., Buonomo, A. R., Zappulo, E., Minei, G., Morisco, F., Borrelli, F., Coppola, N., & Borgia, G. (2014). Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Therapeutics and clinical risk management, 10493-504. https://doi.org/10.2147/TCRM.S66731
Gentile, Ivan, et al. "Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection." Therapeutics and clinical risk management vol. 10 (2014): 493-504. doi: https://doi.org/10.2147/TCRM.S66731
Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag. 2014 Jun 26;10:493-504. doi: 10.2147/TCRM.S66731. eCollection 2014. PMID: 25061308; PMCID: PMC4079632.
Copy Download .nbib Format: NLM
Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals.

Annals of gastroenterology

Alexopoulou A, Karayiannis P.
PMID: 25608803
Ann Gastroenterol. 2015 Jan-Mar;28(1):55-65.

The development of protease inhibitors (PIs) such as telaprevir and boceprevir constitutes a milestone in chronic hepatitis C antiviral treatment since it has achieved sustained virological response (SVR) rates of up to 75% in naïve and 29-88% in treatment-experienced...

Cite
Alexopoulou A, Karayiannis P. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann Gastroenterol. 2015;28(1):55-65
Alexopoulou, A., & Karayiannis, P. (2015). Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Annals of gastroenterology, 28(1), 55-65.
Alexopoulou, Alexandra, and Karayiannis, Peter. "Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals." Annals of gastroenterology vol. 28,1 (2015): 55-65.
Alexopoulou A, Karayiannis P. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann Gastroenterol. 2015 Jan-Mar;28(1):55-65. PMID: 25608803; PMCID: PMC4290005.
Copy Download .nbib Format: NLM
Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection.

American health & drug benefits

Raedler LA.
PMID: 26629267
Am Health Drug Benefits. 2015 Mar;8:54-8.

No abstract available.

Cite
Raedler LA. Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection. Am Health Drug Benefits. 2015;8:54-8
Raedler, L. A. (2015). Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection. American health & drug benefits, 854-8.
Raedler, Lisa A. "Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection." American health & drug benefits vol. 8 (2015): 54-8.
Raedler LA. Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection. Am Health Drug Benefits. 2015 Mar;8:54-8. PMID: 26629267; PMCID: PMC4665066.
Copy Download .nbib Format: NLM
Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C.

ACG case reports journal

Sarkar S, Mitchell KA, Lim JK, Oikonomou I, Jakab S.
PMID: 26504877
ACG Case Rep J. 2015 Oct 09;3(1):42-4. doi: 10.14309/crj.2015.96. eCollection 2015 Oct.

Sofosbuvir and simeprevir are used for the treatment of chronic hepatitis C (HCV) genotype 1. Both drugs have been well-tolerated, with diarrhea noted in 6% cases with sofosbuvir, 16% with sofosbuvir plus simeprevir, and 0% with simeprevir. No prior...

Cite
Sarkar S, Mitchell KA, Lim JK, et al. Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. ACG Case Rep J. 2015;3(1):42-4doi: 10.14309/crj.2015.96.
Sarkar, S., Mitchell, K. A., Lim, J. K., Oikonomou, I., & Jakab, S. (2015). Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. ACG case reports journal, 3(1), 42-4. https://doi.org/10.14309/crj.2015.96
Sarkar, Souvik, et al. "Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C." ACG case reports journal vol. 3,1 (2015): 42-4. doi: https://doi.org/10.14309/crj.2015.96
Sarkar S, Mitchell KA, Lim JK, Oikonomou I, Jakab S. Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. ACG Case Rep J. 2015 Oct 09;3(1):42-4. doi: 10.14309/crj.2015.96. eCollection 2015 Oct. PMID: 26504877; PMCID: PMC4612757.
Copy Download .nbib Format: NLM
Commentary: sofosbuvir for treatment of hepatitis C virus genotype 2 or 3 infection in patients without treatment options.

Gastroenterology & hepatology

Flamm SL.
PMID: 24764786
Gastroenterol Hepatol (N Y). 2013 Oct;9(10):682-3.

No abstract available.

Cite
Flamm SL. Commentary: sofosbuvir for treatment of hepatitis C virus genotype 2 or 3 infection in patients without treatment options. Gastroenterol Hepatol (N Y). 2013;9(10):682-3
Flamm, S. L. (2013). Commentary: sofosbuvir for treatment of hepatitis C virus genotype 2 or 3 infection in patients without treatment options. Gastroenterology & hepatology, 9(10), 682-3.
Flamm, Steven L. "Commentary: sofosbuvir for treatment of hepatitis C virus genotype 2 or 3 infection in patients without treatment options." Gastroenterology & hepatology vol. 9,10 (2013): 682-3.
Flamm SL. Commentary: sofosbuvir for treatment of hepatitis C virus genotype 2 or 3 infection in patients without treatment options. Gastroenterol Hepatol (N Y). 2013 Oct;9(10):682-3. PMID: 24764786; PMCID: PMC3992066.
Copy Download .nbib Format: NLM
Possible Simeprevir/Sofosbuvir-Induced Hepatic Decompensation With Acute Kidney Failure.

Federal practitioner : for the health care professionals of the VA, DoD, and PHS

Nwachukwu J, Johnson R, Mills-Robertson K.
PMID: 30766171
Fed Pract. 2016 Apr;33(4):46-48.

A patient with hepatitis C infection and hepatocellular carcinoma developed significant hyperbilirubinemia and acute kidney injury after initiation of a simeprevir and sofosbuvir regimen.

Cite
Nwachukwu J, Johnson R, Mills-Robertson K. Possible Simeprevir/Sofosbuvir-Induced Hepatic Decompensation With Acute Kidney Failure. Fed Pract. 2016;33(4):46-48
Nwachukwu, J., Johnson, R., & Mills-Robertson, K. (2016). Possible Simeprevir/Sofosbuvir-Induced Hepatic Decompensation With Acute Kidney Failure. Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 33(4), 46-48.
Nwachukwu, Judith, et al. "Possible Simeprevir/Sofosbuvir-Induced Hepatic Decompensation With Acute Kidney Failure." Federal practitioner : for the health care professionals of the VA, DoD, and PHS vol. 33,4 (2016): 46-48.
Nwachukwu J, Johnson R, Mills-Robertson K. Possible Simeprevir/Sofosbuvir-Induced Hepatic Decompensation With Acute Kidney Failure. Fed Pract. 2016 Apr;33(4):46-48. PMID: 30766171; PMCID: PMC6368926.
Copy Download .nbib Format: NLM
Palisaded neutrophilic and granulomatous dermatitis associated with ledipasvir/sofosbuvir.

JAAD case reports

Shenk MER, Ken KM, Braudis K, Fernandez KH.
PMID: 30246134
JAAD Case Rep. 2018 Sep 14;4(8):808-810. doi: 10.1016/j.jdcr.2018.06.025. eCollection 2018 Sep.

No abstract available.

Cite
Shenk MER, Ken KM, Braudis K, et al. Palisaded neutrophilic and granulomatous dermatitis associated with ledipasvir/sofosbuvir. JAAD Case Rep. 2018;4(8):808-810doi: 10.1016/j.jdcr.2018.06.025.
Shenk, M. E. R., Ken, K. M., Braudis, K., & Fernandez, K. H. (2018). Palisaded neutrophilic and granulomatous dermatitis associated with ledipasvir/sofosbuvir. JAAD case reports, 4(8), 808-810. https://doi.org/10.1016/j.jdcr.2018.06.025
Shenk, Mary Elizabeth Reed, et al. "Palisaded neutrophilic and granulomatous dermatitis associated with ledipasvir/sofosbuvir." JAAD case reports vol. 4,8 (2018): 808-810. doi: https://doi.org/10.1016/j.jdcr.2018.06.025
Shenk MER, Ken KM, Braudis K, Fernandez KH. Palisaded neutrophilic and granulomatous dermatitis associated with ledipasvir/sofosbuvir. JAAD Case Rep. 2018 Sep 14;4(8):808-810. doi: 10.1016/j.jdcr.2018.06.025. eCollection 2018 Sep. PMID: 30246134; PMCID: PMC6141673.
Copy Download .nbib Format: NLM
Blocking Zika virus vertical transmission.

Scientific reports

Mesci P, Macia A, Moore SM, Shiryaev SA, Pinto A, Huang CT, Tejwani L, Fernandes IR, Suarez NA, Kolar MJ, Montefusco S, Rosenberg SC, Herai RH, Cugola FR, Russo FB, Sheets N, Saghatelian A, Shresta S, Momper JD, Siqueira-Neto JL, Corbett KD, Beltrão-Braga PCB, Terskikh AV, Muotri AR.
PMID: 29352135
Sci Rep. 2018 Jan 19;8(1):1218. doi: 10.1038/s41598-018-19526-4.

The outbreak of the Zika virus (ZIKV) has been associated with increased incidence of congenital malformations. Although recent efforts have focused on vaccine development, treatments for infected individuals are needed urgently. Sofosbuvir (SOF), an FDA-approved nucleotide analog inhibitor of...

Cite
Mesci P, Macia A, Moore SM, et al. Blocking Zika virus vertical transmission. Sci Rep. 2018;8(1):1218doi: 10.1038/s41598-018-19526-4.
Mesci, P., Macia, A., Moore, S. M., Shiryaev, S. A., Pinto, A., Huang, C. T., Tejwani, L., Fernandes, I. R., Suarez, N. A., Kolar, M. J., Montefusco, S., Rosenberg, S. C., Herai, R. H., Cugola, F. R., Russo, F. B., Sheets, N., Saghatelian, A., Shresta, S., Momper, J. D., Siqueira-Neto, J. L., Corbett, K. D., Beltrão-Braga, P. C. B., Terskikh, A. V., & Muotri, A. R. (2018). Blocking Zika virus vertical transmission. Scientific reports, 8(1), 1218. https://doi.org/10.1038/s41598-018-19526-4
Mesci, Pinar, et al. "Blocking Zika virus vertical transmission." Scientific reports vol. 8,1 (2018): 1218. doi: https://doi.org/10.1038/s41598-018-19526-4
Mesci P, Macia A, Moore SM, Shiryaev SA, Pinto A, Huang CT, Tejwani L, Fernandes IR, Suarez NA, Kolar MJ, Montefusco S, Rosenberg SC, Herai RH, Cugola FR, Russo FB, Sheets N, Saghatelian A, Shresta S, Momper JD, Siqueira-Neto JL, Corbett KD, Beltrão-Braga PCB, Terskikh AV, Muotri AR. Blocking Zika virus vertical transmission. Sci Rep. 2018 Jan 19;8(1):1218. doi: 10.1038/s41598-018-19526-4. PMID: 29352135; PMCID: PMC5775359.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 761 entries